Levosimendan improves event free survival by 50 percent in end-stage heart ... EurekAlert (press release) In a second study, the third generation mineralocorticoid receptor antagonist (MRA) BAY 94-8862 showed improved potassium and kidney tolerance in heart failure patients with chronic kidney disease (CKD). Heart Failure 2013 is the main annual meeting of ... Levosimendan proves safe and effective in end-stage heart failure |
